

Amendments to the Claims:

1. (Currently amended) An immunogenic composition, comprising:
 - a first plasmid vector comprising:
 - a first nucleotide sequence encoding a major outer membrane protein (MOMP) of a strain of *Chlamydia pneumoniae*, said first nucleotide sequence being selected from the group consisting of these having SEQ ID Nos: 12, 13, and or 14 or encoding a MOMP having an amino acid sequence selected from the group consisting of SEQ ID Nos: 15 and 16, and
 - a first promoter sequence operatively coupled to said first nucleotide sequence for expression of said MOMP in a host;
 - a second plasmid vector comprising:
 - a second nucleotide sequence encoding a 76 kDa protein of a strain of *Chlamydia pneumoniae*, said second nucleotide sequence being selected from the group consisting of these having SEQ ID Nos: 1, 2, 3 and or 4, and a second promoter sequence operatively coupled to said second nucleotide sequence for expression of said 76 kDa protein in a host; and
 - a pharmaceutically-acceptable carrier therefor.
2. (Cancelled)
3. (Withdrawn)
4. and 5. (Cancelled)
6. (Previously amended) The immunogenic composition of claim 1 wherein the first promoter is a cytomegalovirus promoter.
7. (Cancelled)
8. (Withdrawn)
9. (Cancelled)

10. (Currently amended) The immunogenic composition of claim 1 wherein said second nucleotide sequence is encodes the 76 kDa protein gene sequence encoding a protein having a molecular size of about 35 kDa and having SEQ ID No: 7.

11. (Currently amended) The immunogenic composition of claim 1 wherein said second nucleotide sequence is encodes the 76 kDa protein gene sequence encoding a protein having a molecular size of about 60 kDa and having SEQ ID No: 8 or 9.

12. (Previously amended) The immunogenic composition of claim 1 wherein said second promoter is a cytomegalovirus promoter.

13. to 17. (Cancelled)

18. (Previously amended) The immunogenic composition of claim 1 wherein said first plasmid vector is pCAMOMP and said second plasmid vector is pCA76kDa.

19. (Currently amended) The immunogenic composition of claim 1 wherein said first and second vectors are present in amounts such that upon administration of the composition to the host, the individual protective effect of the first each vector upon administration of the composition to the host is not adversely affected by the second vector and the protective effect of the second vector is not adversely affected by the first vector other.

20. (Original) The immunogenic composition of claim 1 wherein said first and second vectors are present in amounts such that an enhanced protective effect is achieved in comparison to the individual vectors alone.

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)